Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
about
Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations.Adefovir dipivoxil in the treatment of chronic hepatitis B.Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections.Review article: Nucleoside analogues for the treatment of chronic hepatitis B.Antiviral therapies: focus on hepatitis B reverse transcriptaseTreatment of chronic hepatitis B and the implications of viral resistance to therapy.Current treatment of HIV/hepatitis B virus coinfection.Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients.Future directions in the treatment of HIV-HBV coinfection.Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop.Adefovir dipivoxil in chronic hepatitis B: history and current uses.BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis B virus infection (2005).Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy.BHIVA Guidelines: coinfection with HIV and chronic hepatitis B virus.Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration.
P2860
Q33883722-3CCD7CC3-0AD0-4B6E-8EF7-6A47A17813D3Q35558801-BFD7E827-6842-4B60-AF89-221D80D54FA9Q35635844-303431EE-91A8-4768-927C-CB63271E77F3Q35678267-9026392F-5368-4E3F-B750-90085FDC7A4BQ35917125-5755BAB5-DA0B-4DA5-BD8F-205E739D6E30Q35987869-010D7B13-C84C-4A8D-A47B-8354BCB8BDDBQ36467514-0D5F4035-3098-46B6-897D-4FEBD0DA6EEFQ37124882-86FE5473-2962-40FF-A6FA-52BA306597DEQ37138048-71668C44-8689-4328-95FC-34302B9D0033Q37149701-1D0C28C5-B6C6-4319-A6E3-868F7B114BC2Q37439933-89BFAE99-52A5-4DE2-B150-F3D22AF1A3F7Q37678183-852F877B-84B9-456C-80CF-6458E7F9E3BAQ37975548-F6683B81-E3AB-4E75-B7EA-5E32224CE382Q40406133-676B2C1F-3455-4F7F-BDF1-B63A26C54C8EQ44738460-B3BE135D-2701-4B7A-B8F4-4A2125ACA762Q45711101-5B1636EF-8C88-49D4-B90F-A2E50D8BE208Q46607007-9D5F730D-0949-4C17-9B78-C2EC10C7E050
P2860
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Human immunodeficiency virus ( ...... oxil combined with lamivudine.
@en
type
label
Human immunodeficiency virus ( ...... oxil combined with lamivudine.
@en
prefLabel
Human immunodeficiency virus ( ...... oxil combined with lamivudine.
@en
P2093
P2860
P50
P1476
Human immunodeficiency virus ( ...... oxil combined with lamivudine.
@en
P2093
Anne-Geneviève Marcelin
Constance Delaugerre
Marie-Valérie Bochet
Tony Bombled
Vincent Calvez
Vincent Thibault
Yves Benhamou
P2860
P304
P356
10.1128/AAC.46.5.1586-1588.2002
P407
P577
2002-05-01T00:00:00Z